Amarin Future Growth
Future criteria checks 0/6
Amarin's revenue and earnings are forecast to decline at 5.9% and 11.4% per annum respectively. EPS is expected to decline by 12.9% per annum. Return on equity is forecast to be -8.7% in 3 years.
Key information
-11.4%
Earnings growth rate
-12.9%
EPS growth rate
Biotechs earnings growth | 28.3% |
Revenue growth rate | -5.9% |
Future return on equity | -8.7% |
Analyst coverage | Low |
Last updated | 11 Feb 2025 |
Recent future growth updates
Recent updates
Amarin Corporation plc (NASDAQ:AMRN) Held Back By Insufficient Growth Even After Shares Climb 39%
Jan 24Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation
Jan 03Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues
Oct 29Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 29% Above Their Intrinsic Value Estimate
Aug 01Amarin Corporation plc's (NASDAQ:AMRN) 28% Dip In Price Shows Sentiment Is Matching Revenues
Jun 06Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Apr 16Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding
Mar 12Amarin: Sarissa Is Giving Me Hope Again
Jan 15Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified
Jan 03Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)
Nov 19Investors Don't See Light At End Of Amarin Corporation plc's (NASDAQ:AMRN) Tunnel
Sep 27We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth
Jul 18Is Amarin (NASDAQ:AMRN) In A Good Position To Deliver On Growth Plans?
Nov 11Amarin gains as activist Sarissa starts process for special meeting to replace some board members
Oct 11Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 192 | -73 | N/A | N/A | 1 |
12/31/2026 | 201 | -55 | N/A | N/A | 3 |
12/31/2025 | 169 | -85 | -16 | -2 | 3 |
12/31/2024 | 202 | -55 | 47 | 62 | 3 |
9/30/2024 | 241 | -39 | -19 | -18 | N/A |
6/30/2024 | 265 | -34 | -9 | -9 | N/A |
3/31/2024 | 277 | -53 | 1 | 1 | N/A |
12/31/2023 | 307 | -59 | 6 | 7 | N/A |
9/30/2023 | 322 | -52 | 8 | 9 | N/A |
6/30/2023 | 346 | -38 | -17 | -16 | N/A |
3/31/2023 | 361 | -91 | -89 | -88 | N/A |
12/31/2022 | 369 | -106 | -181 | -180 | N/A |
9/30/2022 | 423 | -92 | -210 | -210 | N/A |
6/30/2022 | 476 | -100 | -196 | -196 | N/A |
3/31/2022 | 536 | -22 | -147 | -147 | N/A |
12/31/2021 | 583 | 8 | -67 | -67 | N/A |
9/30/2021 | 606 | -2 | -77 | -77 | N/A |
6/30/2021 | 620 | 4 | -61 | -61 | N/A |
3/31/2021 | 601 | 1 | -45 | -45 | N/A |
12/31/2020 | 614 | -18 | -22 | -22 | N/A |
9/30/2020 | 590 | -16 | 7 | 8 | N/A |
6/30/2020 | 546 | -13 | 17 | 19 | N/A |
3/31/2020 | 511 | -19 | 30 | 33 | N/A |
12/31/2019 | 430 | -23 | -12 | -9 | N/A |
9/30/2019 | 364 | -63 | -35 | -33 | N/A |
6/30/2019 | 307 | -84 | -83 | -83 | N/A |
3/31/2019 | 259 | -117 | -123 | -123 | N/A |
12/31/2018 | 229 | -116 | -95 | -95 | N/A |
9/30/2018 | 206 | -105 | -65 | -65 | N/A |
6/30/2018 | 198 | -92 | N/A | -43 | N/A |
3/31/2018 | 190 | -71 | N/A | -29 | N/A |
12/31/2017 | 181 | -68 | N/A | -33 | N/A |
9/30/2017 | 166 | -73 | N/A | -50 | N/A |
6/30/2017 | 151 | -78 | N/A | -62 | N/A |
3/31/2017 | 139 | -78 | N/A | -61 | N/A |
12/31/2016 | 130 | -86 | N/A | -72 | N/A |
9/30/2016 | 118 | -81 | N/A | -76 | N/A |
6/30/2016 | 107 | -97 | N/A | -80 | N/A |
3/31/2016 | 91 | -147 | N/A | -96 | N/A |
12/31/2015 | 82 | -149 | N/A | -84 | N/A |
9/30/2015 | 72 | -147 | N/A | -74 | N/A |
6/30/2015 | 64 | -141 | N/A | -72 | N/A |
3/31/2015 | 59 | -62 | N/A | -57 | N/A |
12/31/2014 | 54 | -56 | N/A | -75 | N/A |
9/30/2014 | 48 | -52 | N/A | -92 | N/A |
6/30/2014 | 42 | -75 | N/A | -117 | N/A |
3/31/2014 | 35 | -130 | N/A | -158 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMRN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AMRN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AMRN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AMRN's revenue is expected to decline over the next 3 years (-5.9% per year).
High Growth Revenue: AMRN's revenue is forecast to decline over the next 3 years (-5.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMRN is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/16 10:09 |
End of Day Share Price | 2025/02/14 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amarin Corporation plc is covered by 24 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ritu Baral | Canaccord Genuity |
Chiara Russo | Cantor Fitzgerald & Co. |
Andrew Fein | Chardan Capital Markets, LLC |